Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends ; volume:43 ; number:2 ; day:27 ; month:1 ; year:2023 ; pages:153-154 ; date:2.2023
Clinical drug investigation ; 43, Heft 2 (27.1.2023), 153-154, 2.2023
- Creator
-
Figueiredo, Arnaldo
Costa, Luís
Maurício, Maria Joaquina
Figueira, Luís
Ramos, Rodrigo
Martins-da-Silva, Carlos
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-022-01239-2
- URN
-
urn:nbn:de:101:1-2023041021132602811575
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Figueiredo, Arnaldo
- Costa, Luís
- Maurício, Maria Joaquina
- Figueira, Luís
- Ramos, Rodrigo
- Martins-da-Silva, Carlos
- SpringerLink (Online service)
Other Objects (12)
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Effect of simvastatin on castration-resistant prostate cancer cells
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Effect of simvastatin on castration-resistant prostate cancer cells
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study